Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
12 clinical trials · Condition
◉ Watch Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
| Record | Firm | Date |
|---|---|---|
| Iclusig PMS in CML or Ph+ALL Patients (NCT03709017) | Korea Otsuka Pharmaceutical Co., Ltd. | 2018-08-07 |
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey (NCT03647215) | Incyte Biosciences UK | 2017-12-18 |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium (NCT03678454) | Incyte Biosciences Benelux | 2017-02-03 |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL (NCT02081378) | Novartis Pharmaceuticals | 2014-04-24 |
| Rollover Study of BMS-354825 in Patients With CML and Ph+ALL (NCT01030718) | Bristol-Myers Squibb | 2006-01-01 |
Track Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.